Saturday, 10 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

DISRUPTIVE CAP SHA Stock Over 21% Down In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of DISRUPTIVE CAP SHA (AEX-Index: DCACS.AS) dropped by a staggering 21.28% in 10 sessions from €9.4 to €7.40 at 10:09 EST on Thursday, after five sequential sessions in a row of losses. AEX-Index is falling 0.32% to €739.41, after three consecutive sessions in a row of gains.

About DISRUPTIVE CAP SHA

Disruptive Capital Acquisition Company Limited does not have significant operations. It intends to complete a merger, amalgamation, share exchange, asset and/or liability acquisition, share purchase, reorganization, or related business combination with a target business or entity operating in the financial services sector. The company was incorporated in 2021 and is based in Saint Peter Port, Guernsey.

Volume

Today's last reported volume for DISRUPTIVE CAP SHA is 243 which is 80.8% below its average volume of 745.

More news about DISRUPTIVE CAP SHA (DCACS.AS).

Categories

stockMarket

Tags

Stock PricePrice DownMarket Session NowDCACS.ASStock Price DownStock Market NowMarket SessionStock MarketStockDISRUPTIVE CAP SHA
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com